Premier Alternatives

Neowise Biotechnology

Suzhou, China · Founded 2020 · Privately Held (backing)

Developer of TCR-T (T-cell receptor-based therapy), an immune cell therapy designed for solid tumors. Neowise Biotechnology is based in Suzhou, China and was founded in 2020. Its last reported valuation was $229 million in Oct 2025. It has raised $57.1 million.

Last reported valuation
$229.1M
Oct 2026
Priced at
—
Total raised
$57.1M
Last round
—

Neowise Biotechnology key facts

as of Oct 2026
  • Developer of TCR-T (T-cell receptor-based therapy), an immune cell therapy designed for solid tumors.
  • Neowise Biotechnology is valued at approximately $229.1M as of Oct 2026 (last reported valuation).
  • It has raised $57.1M; the latest was Later Stage VC ($28.1M) in Oct 2025.
  • Notable investors include Suzhou Oriza Holdings Corporation, Baidu Ventures, Leader Venture Capital, Beijing Delian Yuntong Investment Management Company, Marathon Venture Partners — 15 tracked in total.
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$229.1M

Neowise Biotechnology's last reported valuation, Oct 2025. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Neowise Biotechnology with a free account
  • ·The complete investor list: 15 names
  • ·Watch Neowise Biotechnology: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Neowise Biotechnology funding rounds

No rounds on record

No funding rounds for Neowise Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Neowise Biotechnology valuation

Neowise Biotechnology's last reported valuation was $229 million in Oct 2025. No priced round, secondary trade or fund mark has surfaced since.

Neowise Biotechnology investors

15 investors are on record for Neowise Biotechnology, including Suzhou Oriza Holdings Corporation, Baidu Ventures, Leader Venture Capital and Beijing Delian Yuntong Investment Management Company.

About Neowise Biotechnology

Developer of TCR-T (T-cell receptor-based therapy), an immune cell therapy designed for solid tumors. The company offers an antigen-antigen receptor pairing database to efficiently screen for suitable targets and receptor sequences for the treatment of solid tumors, followed by editing, amplification, and functional characterization of T cells, and the return of T cells with high specificity that recognize the patient's tumor surface antigens, providing cancer patients with tumor treatment.

Sector
Healthcare
HQ
Suzhou, China
Founded
2020
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.